Are New Cognitive Tests Ready For Preclinical Trials?
Meet ADCS-PACC, C3: Composites that measure subtle changes in cognition appear reliable, clearing the way for their use in clinical trials of people with presymptomatic AD.
45 RESULTS
Sort By:
Meet ADCS-PACC, C3: Composites that measure subtle changes in cognition appear reliable, clearing the way for their use in clinical trials of people with presymptomatic AD.
Researchers find an actin-binding protein in stress granules, linking the cytoskeleton and RNA sequestration in the pathology of amyotrophic lateral sclerosis.
The latest news on C9ORF72 includes a genetic modifier, various animal models, and a potential treatment to untangle stable, guanine-based structures formed by expanded repeats.
Is transfer of tau from one neuron to the next a normal activity, hijacked by pathogenic protein in the case of tauopathies?
Studies reported at AAIC demonstrate that biomarkers help predict who will develop cognitive impairment and dementia.
AD but no Amyloidβ? Researchers at AAIC 2013 theorized on the pathology underlying this form of dementia.
Hunting for rare mutations that cause dementia, researchers have spotted, but not yet snagged, some tantalizing candidates.
Tau ligands for PET scans were among the hot topics at the Alzheimer’s Association International Conference in Boston.
Removing a key component of the innate immune system worsens amyloid deposition but improves memory in mice that model Alzheimer's pathology.
Protein strains may underlie different tauopathies, according to researchers presented at this year's AAIC meeting in Boston.
Speakers at Alzheimer’s conference reviewed planned Phase 1 and prevention trials and preclinical studies.
Update on compounds in Phase 2 and 3 trials from the Alzheimer's Association International Conference
Researchers at AAIC 2013 report that an individual’s subjective sense of worsening memory could be an important predictor of cognitive impairment and dementia.
At AAIC 2013, researchers present the latest genetic risk factors for Alzheimer's disease.
The proportion of seniors with dementia in England appears to be on the decline, new research suggests.